Identifying stable objective markers of stress-related sleep disturbances: Laboratory and home-based, repeated measurement of cortical hyperarousal and inflammatory upregulation during nocturnal sleep
- Conditions
- Healthy, sub-clinical participants
- Registration Number
- DRKS00030923
- Lead Sponsor
- MU, Medical Faculty, Institute of Medical Psychology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Participants with stress-related sleep disturbances:
(1) 2-3 nightmares / month and/or Athens Insomnia Scale (AIS) score >= 6 (Soldatos, Dikeos, & Paparrigopoulos, 2003); (2) 1 bad dream / week and/or AIS score >= 6
Healthy sleeper control participants:
(1) less than 2-3 nightmares / year and/or AIS score < 4 (Soldatos et al., 2003); (2) not more than 1 bad dream / month and/or AIS score < 4
General:
(1) Prior history of neurological, psychiatric or chronic somatic disorder; (2) regular medication (except contraceptives); (3) drug or alcohol dependency, (4) presence of endocrine or cardiovascular disorder, (5) shift working or other irregular sleep schedule, (6) pregnancy
Participants with stress-related sleep disturbances:
(1) Presence of another sleep disorder (e.g. night terrors, sleep apnea, restless legs syndrome, periodic limb movement disorder)
Healthy sleeper control participants:
same as general exclusion criteria
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cortical hyperarousal, measured by polysomnography and EEG headband, operationalised as increased sleep fragmentation, reduced slow-wave sleep, increased arousal count and reduced slow frequency activity combined with increased fast frequency activity during NREM sleep.<br>Systemic inflammation, measured by the concentration of inflammatory markers in venous (high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6)) and capillary (hsCRP) blood samples and saliva samples (IL-6).
- Secondary Outcome Measures
Name Time Method Smartwatch:<br>o Daily activity level quantified by calculating counts per minute (CPM) from the linear acceleration channel.<br>o Daily questionnaire results in the morning, evening and during stress.<br>Pro-inflammatory and stress markers:<br>o Tumour necrosis factor (TNF), interleukin-1ß (IL-1ß), differential blood count from venous blood sample.<br>o Cortisol, IL-1ß, alpha-amylase from saliva samples.<br>o Cortisol and endocannabinoids from hair samples.<br>Sleep measurements:<br>o Spectral activities during the specified nightmares.<br>o Electrocardiography (ECG) activity (HR, RMSSD, high-frequency and low-frequency spectrum) throughout the night, different sleep periods and registered nightmares.<br>o PPG measurements (HR, RMSSD) throughout the night, different sleep periods and recorded nightmares.